Silo Pharma filings document a Nasdaq-listed Nevada operating company with common stock registered under symbol SILO and a developmental-stage biopharmaceutical business. Its registration statements and offering-related disclosures address registered securities, capital structure, smaller reporting company status, and securities transactions associated with a company developing CNS, psychiatric and chronic-pain therapeutic programs.
Recent 8-K and proxy filings record material agreements, equity issuances, shareholder voting matters, board and compensation-plan actions, and governance changes. Disclosures also cover asset purchases for QwikAgents and cryptocurrency-related software, formation of a cryptocurrency advisory board, registered and private securities transactions, and the amendment of the company’s 2020 omnibus equity incentive plan.
Silo Pharma, Inc. entered into securities purchase agreements with institutional investors for a private placement of its equity and warrants. The structure includes 124,000 shares of common stock at $6.452 per share and pre-funded warrants to purchase up to 495,965 shares of common stock at $6.4519 per warrant, together covering 619,965 shares. Investors also received Series A-3 and Series A-4 warrants to purchase up to 619,965 shares each, all with an exercise price of $6.21 per share, exercisable immediately, with expirations five years and eighteen months, respectively, after the effective date of a resale registration statement. Silo expects aggregate gross proceeds of about $4 million and net proceeds of approximately $3.5 million, and may receive up to roughly $7.7 million in additional gross proceeds if all warrants are exercised for cash. H.C. Wainwright & Co. acted as exclusive placement agent and received a cash fee and warrants for 46,497 shares at an exercise price of $8.065. Net proceeds are intended for working capital and general corporate purposes.
AdvisorShares Trust filed a Schedule 13G reporting beneficial ownership of 6.69% of Silo Pharma, Inc. The filing shows 75,582 shares of common stock (CUSIP 82711P300) as beneficially owned as of 06/30/2026. The report is signed by Stefanie Little, Chief Compliance Officer, on 07/08/2026.
Silo Pharma, Inc. is asking shareholders to vote at its 2026 annual meeting on August 14, 2026 at 11:00 a.m. Eastern in Sarasota, Florida. Holders of common stock as of June 18, 2026, when 1,128,610 shares were outstanding, may vote.
Shareholders will elect four directors, ratify Salberg & Company, P.A. as independent auditor for 2026, consider a common stock increase proposal, and approve a potential adjournment. The board is four members, three of whom are Nasdaq‑independent, and oversees audit, compensation, and nominating committees.
The proxy details executive compensation, including a $350,000 base salary for CEO Eric Weisblum and $60,000 for CFO Daniel Ryweck, plus stock option awards and severance terms for the CEO. It also describes the Amended and Restated 2020 Omnibus Equity Incentive Plan and current equity reserves.
Silo Pharma, Inc. has regained compliance with the Nasdaq minimum bid price requirement. Nasdaq’s Listing Qualifications Staff confirmed that the company’s common stock closed at or above $1.00 per share from June 3, 2026 through June 16, 2026, satisfying Listing Rule 5550(a)(2).
As a result, Silo’s common stock will continue trading on the Nasdaq Capital Market and Nasdaq now considers the matter closed. The company highlighted continued progress toward a first-in-human clinical trial for its PTSD candidate SPC-15 and ongoing development of its AI agents platform QwikAgents.
Silo Pharma, Inc. is soliciting proxies for its 2026 Annual Meeting of Stockholders to be held on August 14, 2026 to vote on four proposals: election of four directors (Proposal 1), ratification of Salberg & Company, P.A. as auditor (Proposal 2), an increase in authorized common stock (Proposal 3), and an adjournment proposal (Proposal 4).
The Board unanimously recommends a vote FOR all four proposals. The record date for voting is June 18, 2026, and proxy materials will be made available beginning on or about June 30, 2026. Shares outstanding were 1,128,610 as of the record date; a quorum requires 376,205 shares. The company effected a 1-for-15 reverse stock split on June 2, 2026. Proxy voting instructions and methods are described in the notice and proxy card.
Silo Pharma, Inc. has implemented a 1-for-15 reverse stock split of its common stock, reclassifying every 15 issued and outstanding shares into one share with the same par value.
At the same time, the company proportionately reduced its authorized common stock to 6,666,667 shares. The reverse split became effective on June 2, 2026, with split-adjusted trading on Nasdaq beginning June 3, 2026 under the existing symbol SILO and a new CUSIP. Outstanding options, warrants, and equity plan reserves were adjusted proportionately, and fractional shares were rounded up to the next whole share. Existing registration statements on Forms S-1 and S-3 are automatically amended so that the amount of shares covered is reduced in line with the 1-for-15 ratio under Rule 416(b).
Silo Pharma is implementing a 1-for-15 reverse stock split of its common stock, with a concurrent proportional cut in authorized shares. The split becomes effective as of 4:01 p.m. Eastern Time on June 2, 2026, and shares will begin trading on a post-split basis on June 3, 2026 under the same symbol, SILO.
Every 15 pre-split shares will be exchanged for 1 post-split share, with fractional positions rounded up to the next whole share. The company expects issued and outstanding shares to decrease from approximately 16.267 million to about 1.084 million. Authorized common stock will be adjusted to 6,666,667 shares, and the share amounts and exercise prices for equity awards, warrants, and plan reserves will be adjusted proportionately.
Silo Pharma reported a Q1 2026 net loss of $1,647,117, wider than a year earlier, as it increased spending on research and development and recorded losses on its cryptocurrency holdings. Revenue remained minimal at $18,026 from license fees, underscoring its early-stage status.
Cash and cash equivalents were $3,902,514 with short-term investments of $2,129,659, supporting working capital of $6,098,849 as of March 31, 2026. Management states this liquidity is sufficient to meet obligations for at least twelve months, easing prior going-concern concerns.
The company advanced its biopharmaceutical pipeline while diversifying, forming AI-focused subsidiary Qwikagentsai and purchasing AI software and domains for $714,000 in stock, all expensed as R&D. It also recorded an impairment of $29,911 on staked crypto assets and unrealized crypto losses, reflecting volatility in its digital asset treasury strategy.
Silo Pharma, Inc. is registering up to 5,023,340 shares of common stock underlying Series A-1 warrants, Series A-2 warrants and placement agent warrants.
The prospectus offers common stock purchase warrants exercisable upon issuance at an exercise price of $0.60 per share; Series A-1 warrants expire five years from the Initial Exercise Date and Series A-2 warrants expire eighteen months from the Initial Exercise Date. The offering price per common stock purchase warrant is $0.60. The company states it will receive proceeds only upon cash exercise of the warrants and may receive up to approximately $3.0 million if all warrants are exercised at the stated price. The company discloses Nasdaq minimum bid-price noncompliance and a second compliance period extending to June 22, 2026, and lists operating losses and cash balances in its historical consolidated financial data.